Effect of pentobarbital anaesthesia on intestinal absorption and hepatic first-pass metabolism of oxacillin in rats, evaluated by portal-systemic concentration difference.
The effects of anaesthesia on intestinal drug absorption and hepatic first-pass metabolism in rats were investigated by observing the difference in the drug concentration between portal and systemic bloods. Oxacillin and pentobarbital were selected as a model drug and as an anaesthetic, respectively. Rats were divided into a conscious control group and an anaesthetized group. All rats were cannulated simultaneously in the portal vein and in the femoral artery, and oxacillin was orally administered after its intra-arterial injection (double dosing). For the anaesthetized group, pentobarbital was intrasubcutaneously administered twice, first before intra-arterial injection and again before oral administration of oxacillin. The arterial blood alone was sampled from the cannula in the femoral artery before oral administration, whereas the arterial and portal bloods were simultaneously sampled from both cannulated sites after oral administration. Oxacillin concentrations in plasma were assayed by HPLC. The anaesthesia increased the absolute bioavailability (F), the mean absorption time (MAT) and the hepatic recovery ratio (F(H)), but caused little change in the local absorption ratio into the portal system (Fa) and the total clearance (CL). The hepatic clearance (CL(H)) was significantly decreased, resulting in an apparent small change in CL-CL(H) which is considered to be renal clearance. By this method, it was shown directly that an increase in F due to pentobarbital anaesthesia was attributable to the significant increase in F(H). It is expected that the method is useful not only to evaluate the effect of anaesthesia on the first-pass effect, but also to assess the effect of co-administration of drugs on first-pass metabolism.
Ueda
S
S
Graduate School of Pharmaceutical Sciences, Kyoto University, Japan.
Yamaoka
K
K
Nakagawa
T
T
D000758:Anesthesia; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D007408:Intestinal Absorption / Q000187:drug effects*; D008099:Liver / Q000378:metabolism*; D008297:Male; D010068:Oxacillin / Q000097:blood / Q000493:pharmacokinetics*; D010406:Penicillins / Q000097:blood / Q000493:pharmacokinetics*; D010424:Pentobarbital / Q000494:pharmacology*; D011168:Portal System / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
D006993:Hypnotics and Sedatives; D010406:Penicillins; D010424:Pentobarbital; D010068:Oxacillin